Drug information of Tafluprost

Tafluprost

Drug group:

Tafluprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye can help prevent blindness. This medication works by regulating the flow of fluid within the eye to maintain a normal pressure

Mechanism of effect

Prostaglandin analog; exact mechanism by which it reduces IOP is unknown, but it is thought to increase uveoscleral outflow

Pharmacodynamic

Tafluprost acid is a fluorinated prostaglandin F2-alpha analog believed to reduce intraocular pressure by increasing outflow of aqueous humor via the uveoscleral pathway

Pharmacokinetics

Bioavailability: Absorbed through the cornea

Onset: 2-4 hr; peak effect at 12 hr

Peak Plasma Time: 10 minutes

Peak Plasma Concentration: 26 pg/mL

AUC: 394-432 pg•min/mL 

Metabolism

Tafluprost is an ester prodrug that is metabolized by hydrolysis to the biologically active acid metabolite (tafluprost acid)

Drug indications

increased ocular tension

Glaucoma

Dosage

drop 0.0015%
Instill 1 drop in affected eye(s) once daily in the evening

Drug contraindications

None

Side effects

Blurred vision , itchy eyes

(Conjunctival hyperemia (4-20%

(Ocular stinging (7%

(Ocular pruritus/allergic conjunctivitis (5%

(Cataract (3%

(Growth of eyelashes (2%

(Blurred vision (2%

 

unoprostone ophthalmic

Alerts

Causes changes to pigmented tissues; most frequently reported changes have been of the iris, eyelid, and eyelashes; pigmentation changes of the iris is likely permanent Increases length, color, thickness, and number of eyelashes

Caution with active intraocular inflammation (may exacerbate condition)

Macular edema reported; caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or with known risk factors for macular edema

Points of recommendation

Instill into conjunctival sac of affected eye

Do not exceed once daily dosing regimen; more frequent administration of prostaglandin analogs may lessen the IOP lowering effect

Reduction of intraocular pressure starts approximately 2 - 4 hours after first administration with maximum effect reached after 12 hr

If other topical ophthalmics are prescribed, each should be administered 5 minutes apart 

Preservative free product; use immediately after opening one unit-dose for administration; sterility cannot be maintained after opening

Pregnancy level

C

teratogenic when administered IV in rats and rabbits

Pregnancy Category: C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done

Breast feeding warning

Unknown whether distributed in breast milk

Related drugs

Latanoprost , latanoprostene bunod , Bimatoprost , Travoprost , unoprostone

 

Latisse

Lumigan

Rescula

Travatan

Travatan Z

unoprostone ophthalmic

Vyzulta

Xalatan

Xelpros

Zioptan

Drug forms

zioptan

Ask a Pharmacist


User's questions
    No comments yet.